title: The impact of optimal stenting techniques on cardiac catheterization laboratory resource utilization and costs.
abstract: Coronary stenting has been shown to reduce angiographic restenosis and improve clinical outcomes compared with conventional balloon angioplasty, but at greater in-lab cost. Recent studies have suggested that "optimal" stent deployment can eliminate the need for intensive oral anticoagulation after stenting, with the potential to reduce vascular complications, length of stay, and hospital cost. Between January and June 1995, we performed elective 1-vessel coronary stenting in 78 patients with a single, discrete (< 15 mm) coronary stenosis (optimal single-lesion group) and in 30 patients with either a single, long stenosis or serial discrete lesions (optimal multilesion group). Compared with stent patients from the Stent Restenosis Study (STRESS) economic substudy, optimal single-lesion stenting required more stents (1.3 +/- 0.6 vs 1.1 +/- 0.4, p <0.01) and more adjunctive angioplasty balloons per patient (2.5 +/- 1.0 vs 2.0 +/- 0.9, p <0.01). As a result, catheterization laboratory costs for single-lesion stenting increased by nearly $600 between 1993 and 1995 ($4,619 +/- $1,120 [median $4,435] to $5,209 +/- $1,697 [median $4,6731, p <0.01). Compared with the STRESS angioplasty group, optimal coronary stenting increased catheterization laboratory costs by nearly $2,200 ($3,012 +/- $1,382 [median $2,548] vs $5,209 +/- $1,697 [median $4,673], p <0.01). Optimal stenting of long lesions or multiple discrete stenoses increased catheterization laboratory costs by an additional $2,000 compared with optimal single-lesion stenting ($7,201 +/- $2,428 [median $6,887] vs $5,209 +/- $1,697 [median $4,673], p <0.01). These findings demonstrate that optimal coronary stenting increases in-lab procedural resource utilization and costs compared with historical stenting techniques. Based on the downstream cost savings seen in the STRESS trial ($1,400/patient), it is unlikely that current optimal stenting techniques will result in an overall cost savings compared with balloon angioplasty.
authors.affiliation: Cardiovascular Division, Beth Israel Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Sukin
authors.forename: D S
authors.initials: DS
authors.lastname: Baim
authors.forename: R P
authors.initials: RP
authors.lastname: Caputo
authors.forename: K K
authors.initials: KK
authors.lastname: Ho
authors.forename: R J
authors.initials: RJ
authors.lastname: Laham
authors.forename: M G
authors.initials: MG
authors.lastname: Flatley
authors.forename: J P
authors.initials: JP
authors.lastname: Carrozza
authors.forename: D J
authors.initials: DJ
authors.lastname: Cohen
mesh_terms: D000368:Aged; D006328:Cardiac Catheterization / Q000191:economics* / Q000706:statistics & numerical data*; D002404:Catheterization / Q000191:economics; D015986:Confounding Factors, Epidemiologic; D003327:Coronary Disease / Q000191:economics* / Q000628:therapy; D003362:Cost-Benefit Analysis; D005260:Female; D017721:Hospital Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D015607:Stents / Q000191:economics* / Q000706:statistics & numerical data*